Core Insights - Merck & Co Inc. reported third-quarter 2025 sales of $17.3 billion, reflecting a 4% increase year-over-year [1] - The company expects full-year sales to be between $64.5 billion and $65 billion, and has raised its non-GAAP EPS forecast to $8.93–$8.98 [3] Sales Performance - KEYTRUDA generated $8.1 billion in sales, marking a 10% increase [2] - WINREVAIR sales surged to $360 million, while CAPVAXIVE contributed $244 million [2] - GARDASIL sales decreased by 24% to $1.7 billion, and Animal Health sales grew by 9% to $1.6 billion [2] Earnings and Financials - Earnings per share were reported at $2.32 (GAAP) and $2.58 (non-GAAP), which included a $0.10 charge related to a tech transfer deal [3] - The company received FDA approval for a new KEYTRUDA injection and shared promising cancer trial data [3] - Merck completed its acquisition of Verona Pharma [3] Company Overview - Merck & Co. Inc. is a global healthcare company focused on scientific innovation to develop health solutions, including prescription medicines, vaccines, biologic therapies, and animal health products [4] - The company's primary focus areas include oncology, vaccines, and infectious diseases [4]